TAK Stock Recent News

Japan's Takeda Pharmaceutical will scale up production of its dengue vaccine Qdenga through a partnership with Indian vaccines maker Biological E., the companies said on Tuesday.

Drugmaker Takeda said on Monday the U.S. Food and Drug Administration has approved its therapy for a type of allergic inflammation of the esophagus, making it the first oral treatment for the condition.

Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript

Takeda Pharmaceutical is one of the top pharma companies in the world. It has a broad mix of products in its portfolio, which can provide investors with some stability.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The U.S. Food and Drug Administration on Thursday approved Takeda Pharmaceutical's therapy to treat a rare genetic blood disorder in adult and pediatric patients.

Pharmaceutical company Takeda 4502, +0.29% said Wednesday that the U.S. Food and Drug Administration approved Fruzaqla as a treatment for certain patients with colorectal cancer.

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2023 Earnings Conference Call October 26, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Head of Investor Relations Christophe Weber - President and Chief Executive Officer Andy Plump - President of R&D Costa Saroukos - Chief Financial Officer Julie Kim - President, U.S. Business Unit and U.S. Country Head Ramona Sequeira - President, Global Portfolio Division Conference Call Participants Hidemaru Yamaguchi - Citigroup Shinichiro Muraoka - Morgan Stanley Seiji Wakao - J.P. Morgan Steve Barker - Jefferies Kazuaki Hashiguchi - Daiwa Securities Michael Nedelcovych - TD Cowen Miki Sogi - Bernstein Akinori Ueda - Goldman Sachs Christopher O'Reilly Thank you very much for joining us out of your busy schedule today for the earnings call for Second Quarter Fiscal 2023 with Takeda Pharmaceutical Company Limited.